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had a mean (SD) age of 43.0 (13.4) and was 95.7% female. Exact
agreement between organ involvement ranged from 47.8% for
blood counts to 86.6% for blood clots. There was signiﬁcant
agreement for involvement of skin/hair/scalp (K = 0.46), kidneys
(K = 0.55), brain (K = 0.54), and blood clots (K = 0.60). Poor
agreement was noted for abnormal blood counts (K = 0.08) and
joint involvement (K = 0.06). CONCLUSION: Similar to studies
of patient-physician agreement on quality of life, stronger agree-
ment between patient and physician assessment was reported for
more physical manifestations of disease. Results suggest there is
opportunity to improve patient management through education
and patient-provider communication.
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OBJECTIVES: To evaluate the impact of product enhancements
such as a new autoinjector (Rebiject II) and ﬁner needles upon
adherence to therapy for patients receiving subcutaneous (sc) Inter-
feron-beta-1a (IFNB-1a) 44 mcg tiw. Injection site reactions (ISRs)
are a common cause of treatment discontinuation in patients with
multiple sclerosis (MS). Support organizations such as the MS Life-
Lines program may help patients manage ISRs, however, simpliﬁ-
cation of the injection process via autoinjectors and ﬁner gauge
needles may also help to decrease ISRs. METHODS: Data were
gathered by the MS LifeLines program between August 2003 and
November 2004 (before product enhancements) and again
between December 2004 and March 2006 (after product enhance-
ments). Patients were contacted by nurse educators at regular inter-
vals and asked a series of questions to determine whether they were
adherent to therapy or had discontinued, and, if they had discon-
tinued, why they had done so. Reasons for discontinuation were
recorded and divided into 3 categories: ISRs, pain and/or burning
at the injection site, or other reasons. RESULTS: Between August
2003 and November 2004, 11,783 total patients received subcu-
taneous (sc) IFNB-1a 44 mcg tiw. Of the 2079 patients who dis-
continued therapy 190 (9.1%) were due to ISRs and 175 (8.4%)
were due to pain and/or burning at the injection site. Between
December 2004 and March 2006, when Rebiject II and ﬁner gauge
needles were incorporated, 12,968 total patients received sc IFNB-
1a 44 mcg tiw. Of the 1780 (13.7%) who discontinued therapy 99
(5.6%) were due to ISRs and 33 (1.9%) were due to pain and/or
burning at the injection site. CONCLUSION: These results demon-
strate that product enhancements have dramatically decreased dis-
continuation of therapy due to overall ISRs and injection pain or
burning in patients administering (sc) IFNB-1a 44 mcg tiw. The
decreased discontinuation to therapy may potentially improve
long-term outcomes.
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OBJECTIVES: To examine differences in the prevalence of other
diseases for patients with and without Alzheimer’s Disease (AD),
and the independent effect of AD on cost, beyond the expected
cost of treating other medical conditions. METHODS: We used
MarketScan Medicare Supplemental and Coordination of Bene-
ﬁts claims data, 2003–2004, for over-age-65 individuals with
Medicare and employer-sponsored plans including drug beneﬁts.
We identiﬁed AD patients by an AD diagnosis or an exclusively
prescribed AD medication in 2003, and selected a demographi-
cally-matched, non-demented Control (3 : 1 ratio to AD). Apply-
ing Diagnostic Cost Groups (DCGs), a comprehensive disease
classiﬁcation and prediction system, we calculated a prospective
relative risk score (RRS) that predicts 2004 costs from non-AD
illnesses in 2003; the mean RRS of all individuals enrolled for
all of 2003 and ≥1 month in 2004 was set to 1.00. We used
regression to estimate AD’s independent effect on cost overall
and among patients with selected non-AD conditions. RESULTS:
The AD Cohort (n = 25,109) is sicker (mean RRS 1.23 vs. 1.04)
than the Controls (n = 75,327); they have more comorbidities
(mean of 8.1 unique medical conditions vs. 6.5) and 34% higher
costs ($13,936 vs. $10,369). However, excess annual costs
attributable to AD are estimated to be only $2307, with outpa-
tient pharmacy being the key driver ($1711 in excess costs). The
AD Cohort has more diabetes, heart, mental health, injuries, vas-
cular, and urinary problems. For patients with certain comor-
bidities (such as, anxiety disorders), excess costs attributable to
AD reach $6000. CONCLUSION: AD patients are sicker than
demographically similar patients, yet cost even more than is
accounted for by their excess morbidity. Much of the additional
cost is due to greater use of outpatient pharmaceuticals.
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OBJECTIVES: To compare the psychometric properties of
migraine speciﬁc health related quality of life instruments based
on McHorney and Tarlov (1995). METHODS: Eleven instru-
ments were identiﬁed based on the following criteria: at least one
peer reviewed publication of the instrument; instrument focus on
HRQOL; psychometric data and instrument availability. Identi-
ﬁed instruments were evaluated based on the McHorney and
Tarlov’s (1995) criteria for individual decision making and
included: item information; administration time (practicality);
instrument breadth; depth (ﬂoor and ceiling effects <15%); 
reliability (internal consistency and test-retest) and validity.
RESULTS: Five migraine speciﬁc health related quality of life
Instruments were identiﬁed: the Migraine Speciﬁc Quality of Life
Questionnaire (MSQ); Migraine Disability Assessment Score
(MIDAS); 24 hr Migraine Speciﬁc Quality of Life Questionnaire
(MQoLQ); Migraine Speciﬁc Quality of Life Measure (MSQOL)
and the Headache Impact Test-6 (HIT-6). Ideal psychometric
properties were not shown by any of the ﬁve instruments evalu-
ated based on study criteria. This was in part due to lacking 
psychometric data in addition to failure to meet study criteria.
For example, MSQ was the only questionnaire available with
reported depth and internal consistency data. MSQ, MIDAS,
MQoLQ were the most frequently used questionnaires. MSQ
was notable for the most extensive psychometric data to support
the scale including adequate item information, breadth, depth
(ﬂoor and ceiling effects <10%) and validity (multitrait-multi-
method, convergent, known groups and conﬁrmatory factor
analysis). Although internal consistency for all the dimensions of
MSQ (α = 0.86–0.96) was adequate for group level decision
